Hamilton TD, et al. - Researchers performed a cost-effectiveness analysis of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treating peritoneal carcinomatosis (PC) from metastatic colorectal cancer (mCRC) in the US. A Markov model was developed to determine the cost-effectiveness of CRS/HIPEC vs systemic chemotherapy for isolated PC from mCRC. Outcomes support the cost-efficacy of the CRS/HIPEC treatment during the majority of simulations in the probabilistic sensitivity analyses (PSA). The average incremental cost-effectiveness ratio for 100,000 simulations was $70,807 per quality-adjusted-life-year (QALY) gained in the PSA vs $91,034 per QALY gained with systemic chemotherapy.